Page 193 - 2021_07-Haematologica-web

Lenalidomide induction and maintenance in MM
plus vorinostat (n=196, not included in this further analy- sis), or to observation (n=377). The baseline characteristics of patients undergoing maintenance randomization were well balanced between the two treatment groups (Online Supplementary Table S2). Approximately half of patients in both the lenalidomide and observation groups had received CRD as induction therapy (230 of 451 [51.0%] in
the lenalidomide group; 190 of 377 [50.4%] in the obser- vation group). Lenalidomide maintenance was associated with significantly longer PFS and OS compared with observation in transplant-eligible patients (median: 50 vs. 28 months; HR, 0.47; 95% CI: 0.37-0.60; P<0.0001 at a median follow-up of 27.2 [IQR, 12.8-42.0] months).
In a post-hoc exploratory analysis, the longest PFS was
A
B
Figure 3. Outcomes according to induction and maintenance treatment. (A) Progression-free survival and (B) overall survival. CRD: cyclophosphamide, lenalidomide, and dexamethasone; CTD: cyclophosphamide, thalidomide, and dexamethasone; Obs: observation; Len: lenalidomide.
haematologica | 2021; 106(7)
1963